[go: up one dir, main page]

SV2011003997A - Pirimidinas fusionadas - Google Patents

Pirimidinas fusionadas

Info

Publication number
SV2011003997A
SV2011003997A SV2011003997A SV2011003997A SV2011003997A SV 2011003997 A SV2011003997 A SV 2011003997A SV 2011003997 A SV2011003997 A SV 2011003997A SV 2011003997 A SV2011003997 A SV 2011003997A SV 2011003997 A SV2011003997 A SV 2011003997A
Authority
SV
El Salvador
Prior art keywords
fusionated
pyrimidins
tautomer
stereoisomer
salt
Prior art date
Application number
SV2011003997A
Other languages
English (en)
Inventor
Matthias Vennemann
Thomas Baer
Thomas Maier
Swen Hoelder
Gerrit Beneke
Florian Dehmel
Armin Zuelch
Andreas Strub
Thomas Beckers
Stuart Ince
Ningshu Liu
Ulf Boemer
Hartmut Rehwinkel
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of SV2011003997A publication Critical patent/SV2011003997A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

COMPUESTOS DE LA FÓRMULA (I): (VER FORMULA); UN N-ÓXIDO, UNA SAL, UN TAUTÓMERO O UN ESTEREOISÓMERO DE DICHO COMPUESTO, O UNA SAL DE DICHO N-ÓXIDO, TAUTÓMERO O ESTEREOISÓMERO, EN DONDE EL ANILLO B Y LA PIRIMIDINA A LA CUAL ESTÁ FUSIONADO, R4, R5, R6, R7, M Y N TIENEN LOS VALORES INDICADOS EN LA DESCRIPCIÓN Y EN LAS REIVINDICACIONES, QUE SON INHIBIDORES EFICACES DE LA VÍA PI3K/AKT, PROCESOS PARA SU PRODUCCIÓN Y SU USO COMO FÁRMACOS
SV2011003997A 2009-02-13 2011-08-12 Pirimidinas fusionadas SV2011003997A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075072 2009-02-13
EP09152914 2009-02-16

Publications (1)

Publication Number Publication Date
SV2011003997A true SV2011003997A (es) 2012-01-06

Family

ID=42115325

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2011003997A SV2011003997A (es) 2009-02-13 2011-08-12 Pirimidinas fusionadas

Country Status (28)

Country Link
US (1) US8957064B2 (es)
EP (1) EP2396330B1 (es)
JP (1) JP5777526B2 (es)
KR (1) KR20110114663A (es)
CN (1) CN102317291B (es)
AR (1) AR075253A1 (es)
AU (1) AU2010213192A1 (es)
BR (1) BRPI1008782A2 (es)
CA (1) CA2752105C (es)
CL (1) CL2011001972A1 (es)
CO (1) CO6410298A2 (es)
CR (1) CR20110432A (es)
CU (1) CU20110159A7 (es)
DO (1) DOP2011000260A (es)
EA (1) EA201101186A1 (es)
EC (1) ECSP11011258A (es)
ES (1) ES2580779T3 (es)
IL (1) IL213953A0 (es)
MA (1) MA33032B1 (es)
MX (1) MX2011008583A (es)
PE (1) PE20120534A1 (es)
SG (1) SG172898A1 (es)
SV (1) SV2011003997A (es)
TN (1) TN2011000404A1 (es)
TW (1) TW201036978A (es)
UY (1) UY32432A (es)
WO (1) WO2010091808A1 (es)
ZA (1) ZA201106663B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2694058C (en) * 2007-08-14 2016-06-07 Bayer Schering Pharma Aktiengesellschaft Fused bicyclic pyrimidines
ES2539257T3 (es) 2010-07-28 2015-06-29 Bayer Intellectual Property Gmbh Imidazo[1,2-b]piridazinas sustituidas
EP2651949B1 (en) * 2010-12-16 2015-07-15 Bayer Intellectual Property GmbH Substituted pyrimido[1,2-b]indazoles and their use as modulators of the pi3k/akt pathway
PH12013502073A1 (en) 2011-04-07 2014-01-13 Bayer Ip Gmbh Imidazopyridazines as akt kinase inhibitors
WO2013152717A1 (zh) 2012-04-10 2013-10-17 上海昀怡健康管理咨询有限公司 稠合嘧啶类化合物，其制备方法，中间体，组合物和应用
CA2897279C (en) 2013-01-23 2020-12-29 Astrazeneca Ab Aminopyrazine derivatives and pharmaceutical compositions thereof for use in the treatment of cancer
CN104513254B (zh) 2013-09-30 2019-07-26 上海璎黎药业有限公司 稠合嘧啶类化合物、中间体、其制备方法、组合物和应用
CN104557872B (zh) 2013-10-16 2017-05-24 上海璎黎药业有限公司 稠合杂环化合物、其制备方法、药物组合物和用途
LT3472160T (lt) * 2016-06-16 2021-04-26 Janssen Pharmaceutica Nv Biciklinio piridino, pirazino ir pirimidino dariniai kaip pi3k beta inhibitoriai
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase
EP3600328A4 (en) 2017-03-24 2021-01-06 3100 Central Expressway LLC MERGED TRIAZOLO-PYRIMIDINE COMPOUNDS WITH USEFUL PHARMACEUTICAL APPLICATION
US11130751B2 (en) 2017-03-29 2021-09-28 Janssen Pharmaceutica Nv Quinoxaline and pyridopyrazine derivatives as PI3K-beta inhibitors
BR112021009832A2 (pt) 2018-11-21 2021-08-17 Case Western Reserve University composições e métodos de modulação da atividade da desidrogenase de cadeia curta
WO2020159942A1 (en) * 2019-01-29 2020-08-06 Tosk, Inc. Pyrazolopyrimidine modulators of ras gtpase
US20220227772A1 (en) * 2019-05-07 2022-07-21 The Trustees Of The University Of Pennsylvania Deuterated triazolopyrimidines
CN112921405B (zh) * 2019-12-05 2023-06-27 成都先导药物开发股份有限公司 一种合成On-DNA吡唑并[1，5-a]嘧啶化合物的方法
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
GB2600384A (en) 2020-09-30 2022-05-04 Vaderis Therapeutics Ag Allosteric AKT inhibitors for use in the treatment of hereditary hemorrhagic telangiectasia
US12180220B2 (en) 2020-10-14 2024-12-31 Tosk, Inc. Heteroaryl modulators of RAS GTPase
CN114874221A (zh) * 2022-05-12 2022-08-09 广州佳途科技股份有限公司 一种rip2激酶抑制剂中间体及其合成方法
CN118359616A (zh) * 2023-01-19 2024-07-19 中国科学院上海有机化学研究所 一种作为治疗神经系统疾病和肿瘤的多环化合物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1541615A (en) * 1975-06-26 1979-03-07 Philip Morris Inc Azetidine compounds and process for their production
GB1543308A (en) 1975-06-26 1979-04-04 Philip Morris Inc Azetidine compounds and process for their production
ES2187792T3 (es) 1996-06-25 2003-06-16 Gore W L & Ass Gmbh Compuestos flexibles resistentes al agua y a aceites.
TW414846B (en) 1997-11-05 2000-12-11 Mitsubishi Heavy Ind Ltd Combustion apparatus
GB9821898D0 (en) * 1998-10-08 1998-12-02 Pfizer Ltd Heterocycles
JP2006507299A (ja) * 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害薬
CA2522430A1 (en) * 2003-04-24 2004-11-11 Merck & Co., Inc. Inhibitors of akt activity
AU2004233828B2 (en) 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2005233584B2 (en) 2004-04-09 2010-12-09 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1736472A4 (en) * 2004-04-15 2007-10-31 Astellas Pharma Inc 2-aminopyridine derivative
AP2006003824A0 (en) 2004-05-27 2006-12-31 Pfizer Aminopyridine derivatives as selective dopamine D3agonists
AU2005290081B2 (en) 2004-08-23 2010-12-02 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
AU2005316826A1 (en) 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
EP1850843A4 (en) 2005-02-14 2012-02-15 Merck Sharp & Dohme INHIBITORS OF ACT ACTIVITY
ES2409168T3 (es) 2005-06-10 2013-06-25 Merck Sharp & Dohme Corp. Inhibidores de la actividad Akt
AU2006299338A1 (en) * 2005-10-06 2007-04-12 Merck Sharp & Dohme Corp. Pyrazolopyrimidines as protein kinase inhibitors
BRPI0616985B1 (pt) * 2005-10-06 2021-10-26 Merck Sharp & Dohme Corp. Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto
DE602007004750D1 (de) 2006-11-02 2010-03-25 Vertex Pharma Als inhibitoren von proteinkinasen geeignete aminopyridine und aminopyrimidine
DK2497470T3 (en) * 2006-11-22 2015-12-07 Incyte Holdings Corp Imidazotriaziner and imidazopyrimidines as kinase inhibitors
CA2694058C (en) * 2007-08-14 2016-06-07 Bayer Schering Pharma Aktiengesellschaft Fused bicyclic pyrimidines

Also Published As

Publication number Publication date
HK1165423A1 (en) 2012-10-05
ECSP11011258A (es) 2011-10-31
WO2010091808A8 (en) 2011-07-21
US20130317002A1 (en) 2013-11-28
KR20110114663A (ko) 2011-10-19
CN102317291B (zh) 2015-02-11
IL213953A0 (en) 2011-08-31
EP2396330B1 (en) 2016-04-06
MX2011008583A (es) 2011-12-12
EA201101186A1 (ru) 2012-04-30
US8957064B2 (en) 2015-02-17
ZA201106663B (en) 2013-03-27
CO6410298A2 (es) 2012-03-30
AR075253A1 (es) 2011-03-16
CL2011001972A1 (es) 2012-03-23
EP2396330A1 (en) 2011-12-21
MA33032B1 (fr) 2012-02-01
UY32432A (es) 2010-09-30
JP2012517963A (ja) 2012-08-09
JP5777526B2 (ja) 2015-09-09
BRPI1008782A2 (pt) 2019-09-24
AU2010213192A1 (en) 2011-08-04
WO2010091808A1 (en) 2010-08-19
CN102317291A (zh) 2012-01-11
CA2752105A1 (en) 2010-08-19
DOP2011000260A (es) 2011-10-15
SG172898A1 (en) 2011-08-29
PE20120534A1 (es) 2012-05-10
CR20110432A (es) 2011-10-24
CA2752105C (en) 2017-10-31
ES2580779T3 (es) 2016-08-26
CU20110159A7 (es) 2012-02-15
TW201036978A (en) 2010-10-16
TN2011000404A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
SV2011003997A (es) Pirimidinas fusionadas
CR20160191A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
MX376271B (es) Compuestos heterocíclicos y usos de los mismos.
CR20140089A (es) Nuevos derivados bicíclicos de dihidroquinolina-2-ona
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
CR20140106A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX345763B (es) Nuevos macrociclos como inhibidores del factor xia.
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
CR20200276A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059)
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
UY35325A (es) Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep
ECSP19013196A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2
CU20180028A7 (es) DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, ÚTILES COMO INHIBIDORES DUALES DE DYRK1/CLK1 Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN